Skip to main content

Advertisement

SpringerLink
Log in

Current controversies in the management of breast cancer

  • Special Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

An Erratum to this article was published on 29 April 2010

Abstract

The following manuscript summarises the content of the Breast Symposium that was held in May 2008 in Barcelona in which four controversies regarding the management of breast cancer were discussed. The design of the symposium included two speakers per controversy, one in favour and one diverging, and the audience had to vote before and after the presentations to assess changes in the participants’ views. The four controversies included: (1) the role of non-conventional predictive factors in selecting treatment for breast cancer; (2) the role of surgery in disseminated disease; (3) are taxanes indicated in the adjuvant treatment of patients with lymph-node-negative disease?; (4) is treatment with tamoxifen (TAM) always required after surgery in patients with ductal carcinoma in situ (DCIS)? The symposium concluded with the presentation titled: ‘Features of a well designed clinical trial in the adjuvant treatment of breast cancer’.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752

    Article  CAS  PubMed  Google Scholar 

  2. Pollack JR, Sorlie T, Perou CM et al (2002) Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 99:12963–12968

    Article  CAS  PubMed  Google Scholar 

  3. Fan C, Oh DS, Wessels L et al (2006) Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 355:560–569

    Article  CAS  PubMed  Google Scholar 

  4. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826

    Article  CAS  PubMed  Google Scholar 

  5. Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726–3734

    Article  CAS  PubMed  Google Scholar 

  6. Chia SK, Speers CH, D’yachkova Y et al (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110:973–979

    Article  PubMed  Google Scholar 

  7. Hess DA, Klomp HM (2006) The role of surgery for pulmonary metastases in breast cancer patients. Breast Cancer Online

  8. Adam R, Aloia T, Krissat J et al (2006) Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg 244: 897–908

    Article  PubMed  Google Scholar 

  9. Posner JB (1990) Surgery for metastases to the brain. N Engl J Med 322:544–545

    CAS  PubMed  Google Scholar 

  10. Khan SA, Stewart AK, Morrow M (2002) Does aggressive local therapy improve survival in metastic breast cancer. Surgery 32:620–628

    Article  Google Scholar 

  11. Rapiti E, Verkooijen HM, Vlastos G et al (2006) Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 24:2743–2749

    Article  PubMed  Google Scholar 

  12. Gnerlich J, Jeffe DB, Deshpande A et al (2007) Surgical removal of the primary tumor increases overall survival in patients with metastatic breast cancer: analysis of the 1988–2003 SEER Data. Ann Surg Oncol 14:2187–2194

    Article  PubMed  Google Scholar 

  13. Babiera GV, Rao R, Feng L et al (2006) Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 13:776–782

    Article  PubMed  Google Scholar 

  14. Blanchard DK, Shetty PB, Hilsenbeck SG, Elledge RM (2008) Association of surgery with improved survival in stage IV breast cancer patients. Ann Surg 247:732–738

    Article  PubMed  Google Scholar 

  15. Barkley CR, Bafford AC, Burstein HJ et al (2007) Breast surgery for women presenting with Stage IV breast cancer. Program and abstracts of the 30th Annual San Antonio Breast Cancer Symposium; December 13–16; San Antonio, TX. Abstract 5085

  16. Adam R, Aloia T, Krissat J et al (2006) Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg 244:897–908

    Article  PubMed  Google Scholar 

  17. Elias D, Maisonnette F, Druet-Cabanac M, et al (2003) An attempt to clarify indications for hepatectomy for liver metastases for liver metastases from breast cancer. Am J Surg 185:158–164

    Article  PubMed  Google Scholar 

  18. Friedel G, Pastorino U, Ginsberg RJ et al (2002) Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the International Registry of Lung Metastases. Eur J Cardiothorac Surg 22:335–344

    Article  PubMed  Google Scholar 

  19. Planchard D (2004) Uncertain benefit from surgery in patients with lung metastases from breast carcinoma. Cancer 100:28–35

    Article  PubMed  Google Scholar 

  20. Tanaka F, Li M, Hanaoka N et al (2005) Surgery for pulmonary nodules in breast cancer patients. Ann Thorac Surg 79:1711–1715

    Article  PubMed  Google Scholar 

  21. Ferguson T, Wilcken N, Vagg R et al (2007) The Cochrane Library, issue 4

  22. De Laurentiis M, Cancello G, D’Agostino D, et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26:44–53

    Article  PubMed  CAS  Google Scholar 

  23. Jones SE, Savin MA, Holmes FA et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24:5381–5387

    Article  CAS  PubMed  Google Scholar 

  24. Martin M, Lluch A, Seguí MA et al (2006) Toxicity and health related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocytecolony stimulating factor to the TAC regimen. Ann Oncol 17:1205–1212

    Article  CAS  PubMed  Google Scholar 

  25. Hershman D, Neugut AI, Jacobson JS et al (2007) Acute myeloid leukaemia or myelodysplastic syndrome following use of granulocyte colonystimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 99:196–205

    Article  CAS  PubMed  Google Scholar 

  26. Patt DA, Duan Z, Fang S et al (2007) Acute myeloid leukaemia after adjuvant breast cancer therapy in older women: understanding risk. J Clin Oncol 25:3871–3876

    Article  PubMed  Google Scholar 

  27. Wolowacz SE, Cameron DA, Tate HC, Bagust A (2008) Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis. J Clin Oncol 26:925–933

    Article  CAS  PubMed  Google Scholar 

  28. Ward S, Simpson E, Davis S et al (2007) Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess 11:1–144

    Google Scholar 

  29. Gianni L, Baselga J, Eiermann V et al (2005) European Cooperative Trial in Operable Breast Cancer (ECTO): improved freedom from progression (FFP) from adding paclitaxel (T) to doxorubicin (A) followed by cyclophosphamide methotrexate and fluorouracil (CMF). J Clin Oncol (ASCO Annual Meeting Proceedings) 23[16S, Part I of II (June 1 Supplement)]:513

    Google Scholar 

  30. Martín M, Lluch A, Seguí MA et al (2008) Effect of docetaxel-based adjuvant chemotherapy on disease-free survival in patients with high-risk nodenegative breast cancer: results from the GEICAM 9805 trial. Breast Cancer Symposium, abstr 153

  31. Jones SE, Savin MA, Holmes FA et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 24: 5381–5387

    Article  CAS  PubMed  Google Scholar 

  32. Jones S, Holmes F, O’shaughnessy J et al (2007) Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. Breast Cancer Res Treat 106[Suppl 1]:S5 [Abstract 12]

    Google Scholar 

  33. Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678–5685

    Article  CAS  PubMed  Google Scholar 

  34. De Laurentiis M, Cancello G, D’Agostino D et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26:44–53

    Article  PubMed  CAS  Google Scholar 

  35. Berry DA, Cirrincione C, Craig Henderson I et al (2006) Oestrogen-receptor status and outcomes of modern chemotherapy for patients with nodepositive breast cancer. JAMA 295:1658–1667

    Article  CAS  PubMed  Google Scholar 

  36. Andre F, Broglio K, Roche H et al (2007) Estrogen receptor expression and efficacy of docetaxel in early breast cancer: a pooled analysis of 3,490 patients included in two randomized trials. Proc Am Soc Clin Oncol 25:Abstract 537

  37. Jacquemier J, Penault-Llorca, Mnif H et al (2006) Identification of a basal-like subtype and comparative effect of epirubicin-based chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 breast cancer trial: 33 markers studied on tissue microarrays. Proc Am Soc Clin Oncol 24:5s, Abstract 509

    Google Scholar 

  38. Hayes N, Thor A, Dressler L et al (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496–1506

    Article  CAS  PubMed  Google Scholar 

  39. Rodríguez-Lescure A, Martín M, Ruiz A et al (2007) Subgroup analysis of GEICAM 9906 trial comparing six cycles of FE90C (FEC) to four cycles of FE90C followed by 8 weekly paclitaxel administrations (FECP): relevance of HER2 and hormonal status (HR). J Clin Oncol (ASCO Annual Meeting Pr ceedings Part I) 25[18S]:10598

    Google Scholar 

  40. Pritchard KI, Messersmith H, Elavathil L et al (2008) HER-2 and topoisomerase II as predictors of response to chemotherapy. J Clin Oncol 26:736 744

    PubMed  Google Scholar 

  41. Kumar R (2007) ErbB-dependent signalling as a determinant of trastuzumab resistance. Clin Cancer Res 13:4657–4659

    Article  CAS  PubMed  Google Scholar 

  42. Rouzier R, Rajan R, Wagner P et al (2005) Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 102:8315–8320

    Article  CAS  PubMed  Google Scholar 

  43. Dumontet CM, Reed JC, Krajewska M et al (2007) BCIRG 001 molecular analysis: identification of prognostic factors in patients (pts) receiving adjuvant therapy for node-positive (N+) breast cancer (BC). J Clin Oncol (ASCO Annual Meeting Proceedings Part I) 25 [18S (June 20 Supplement)]:525

    Google Scholar 

  44. Andre F, Mazouni C, Liedtke C et al (2008) HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res 108:183–190

    Article  CAS  Google Scholar 

  45. Li CL, Daling JR, Malone KE (2005) Age-specific incidence rates of in situ breast carcinomas by histologic type, 1980 to 2001. Cancer Epidem Biom Prev 14:1008–1011

    Article  Google Scholar 

  46. Fisher B, Dignam J, Wolmark N et al (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441–452

    CAS  PubMed  Google Scholar 

  47. Li CI, Malone KE, Saltzman BS, Daling JR (2006) Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988–2001. Cancer 106:2104–2112

    Article  PubMed  Google Scholar 

  48. Lee LA, Silverstein MJ, Chung CT et al (2006) Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinomain-situ of the breast. Am J Surg 192:416–419

    Article  PubMed  Google Scholar 

  49. Narran EO, Gonzalez-Angulo AM, Giordano SH et al (2007) Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 25:4952–4960

    Article  Google Scholar 

  50. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

    Article  CAS  Google Scholar 

  51. Van Gestel YR, Voogd AC, Vingerhoets AJ (2007) A comparison of quality of life, disease impact and risk perception in women with invasive breast cancer and ductal carcinoma in situ. Eur J Cancer 43:549–556

    Article  PubMed  Google Scholar 

  52. Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652–1662

    Article  CAS  PubMed  Google Scholar 

  53. Veronesi U, Maisonneuve P, Rotmensz N (2007) Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99:727–737

    Article  CAS  PubMed  Google Scholar 

  54. Cuzick J, Forbes JF, Sestak I et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer: 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272–282

    Article  CAS  PubMed  Google Scholar 

  55. Powles TJ, Ashley S, Tidy A et al (2007) Twentyyear follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283–290

    Article  CAS  PubMed  Google Scholar 

  56. Fisher B, Dignam J, Wolmark N et al (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993–2000

    Article  CAS  PubMed  Google Scholar 

  57. Silverstein MJ, Barth A, Poller DN et al (1995) Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur J Cancer 31A:1425–1427

    Article  CAS  PubMed  Google Scholar 

  58. Cutuli B, Cohen-Solal-Le Nir C, De Lafontan B et al (2001) Ductal carcinoma in situ of the breast results of conservative and radical treatments in 716 patients. Eur J Cancer 37:2365–2372

    Article  CAS  PubMed  Google Scholar 

  59. Houghton J, George WD, Cuzick J et al (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362:95–102

    Article  PubMed  Google Scholar 

  60. Rakovitch E, Franssen E, Kim J et al (2003) A comparison of risk perception and psychological morbidity in women with ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res Treat 77:285–293

    Article  PubMed  Google Scholar 

  61. Hudis CA, Barlow WE, Costantino JP et al (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP System. J Clin Oncol 25:2127–2132

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Hospital del Mar-IMAS, Barcelona, Spain

    Ignasi Tusquets & Joan Albanell

  2. Department of Medical Oncology, Centro Integral Oncológico Clara Campal, Madrid, Spain

    Laura García-Estévez

  3. Department of Medical Oncology, Hospital de Alicante, Alicante, Spain

    Encarna Adrover

  4. Department of Medical Oncology, Complejo Hospitalario Universitario Juan Canalejo, La Coruña, Spain

    Lourdes Calvo

  5. Department of Medical Oncology, Hospital Donostia, San Sebastián, Spain

    Isabel Álvarez

  6. Department of Medical Oncology, Complejo Hospitalario Ourense, Ourense, Spain

    Jesús García Mata

  7. Department of Medical Oncology, HUCA, Oviedo, Spain

    Yolanda Fernández

  8. Department of Medical Oncology Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

    Mireia Margueli & Agusti Barnadas

  9. Department of Medical Oncology, Consorci Sanitari Parc Taulí, Sabadell, Barcelona, Spain

    Miquel Ángel Seguí

  10. Department of Medical Oncology, Hospital Universitario de Salamanca, Salamanca, Spain

    César Rodríguez

  11. Department of Medical Oncology, Hospital General Universitario de Elche Elche, Alicante, Spain

    Álvaro Rodríguez Lescure

  12. Department of Medical Oncology, Centro Oncológico MD Anderson España, Madrid, Spain

    Ramon Colomer

  13. Department of Medical Oncology, Hospital Clínic Barcelona, Barcelona, Spain

    Pere Gascón

  14. Department of Medical Oncology, Hospital Universitario San Carlos, Madrid, Spain

    Miguel Martín

  15. Department of Medical Oncology, Hospital Clínico Universitario, Málaga, Spain

    Emilio Alba

  16. Department of Medical Oncology, Hospital Universitario Arnau Vilanova, Lleida, Spain

    Antonio Llombart

  17. Department of Medical Oncology, Hospital Clínico Universitario de Valencia, Valencia, Spain

    Ana Lluch

  18. Servicio de Oncología Médica Unidad Funcional de Patología Mamaria, Hospital del Mar. IMAS, Passeig Maritim, 25-29, ES-08003, Barcelona, Spain

    Ignasi Tusquets

Authors
  1. Ignasi Tusquets
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura García-Estévez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Encarna Adrover
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lourdes Calvo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Isabel Álvarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jesús García Mata
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yolanda Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mireia Margueli
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Miquel Ángel Seguí
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. César Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Álvaro Rodríguez Lescure
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Ramon Colomer
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Pere Gascón
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Miguel Martín
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Emilio Alba
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Agusti Barnadas
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Antonio Llombart
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Joan Albanell
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Ana Lluch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ignasi Tusquets.

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/s12094-010-0558-9.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tusquets, I., García-Estévez, L., Adrover, E. et al. Current controversies in the management of breast cancer. Clin Transl Oncol 12, 278–286 (2010). https://doi.org/10.1007/s12094-010-0504-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-010-0504-x

Keywords

Search

Navigation